Skip to main navigation

Main Nav

About Us
Scientific Platform
Our Pipeline
Career Opportunities
Investors & Media

Press Releases

IR Nav

Overview
Press Releases
Events
Presentations
Annual Reports
Corporate Governance
SEC Filings
Stock Information
Analyst Coverage
FAQs
Email Alerts
Investor Contact

Shareholder Tools

Press Releases

Year

Gritstone Announces Results from Preclinical Study of its Self-amplifying mRNA (samRNA) Vaccine Against SARS-CoV-2 Published in Nature Communications

June 10, 2022

Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 8, 2022

Gritstone Earns 2022 Great Place to Work Certification™

June 2, 2022

Gritstone Announces Updated Overall Survival Results in Advanced Colorectal Cancer Patients from Phase 1/2 Study of GRANITE and Trial in Progress Poster at ASCO

May 31, 2022

Gritstone to Participate in H.C. Wainwright Global Investment Conference

May 17, 2022

Gritstone Reports First Quarter 2022 Financial Results and Provides Business Update

May 6, 2022

Gritstone to Release First Quarter 2022 Financial Results on May 5 and Announces Q&A Opportunity for Shareholders

May 2, 2022

Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 27, 2022

Gritstone Presentations at AACR Further Support Expertise in Neoantigen Vaccine Design and Delivery

April 12, 2022

Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 30, 2022

Pagination

First page
Previous page
…
Page 5
Page 6
Page 7
Page 8
Current page 9
Page 10
Page 11
Page 12
Page 13
…
Next page
Last page

© 2024 Gritstone Bio |

Footer Links

Privacy Policy
Terms of Use
Cookie Policy
Contact

socials

Top